Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors

References

• FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Int J Cancer20151365E359E38625220842
   PubMed Web of Science ®Google Scholar
• American Cancer SocietyCancer Facts & Figures, 2014Atlanta, GAAmerican Cancer Society2014
   Google Scholar
• ArgirisAKaramouzisMVRabenDFerrisRLHead and neck cancerLancet200837196251695170918486742
   PubMed Web of Science ®Google Scholar
• BlotWJMcLaughlinJKWinnDMSmoking and drinking in relation to oral and pharyngeal cancerCancer Res19884811328232873365707
   PubMed Web of Science ®Google Scholar
• GillisonMLChaturvediAKLowyDRHPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and womenCancer200811310 Suppl3036304618980286
   PubMed Web of Science ®Google Scholar
• SturgisEMCinciripiniPMTrends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?Cancer200711071429143517724670
   PubMed Web of Science ®Google Scholar
• KleinGThe relationship of the virus to nasopharyngeal carcinomaEpsteinMAchongBThe Epstein-Barr VirusBerlin, GermanySpringer-Verlag1979339350
   Google Scholar
• SeiwertTYCohenEEState-of-the-art management of locally advanced head and neck cancerBr J Cancer20059281341134815846296
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology™Head and Neck Cancers. Version 22014 Available from: http://www.nccn.org/professionals/physician_gls/PDF/head-and-neck.pdfAccessed September 22, 2014
   Google Scholar
• GibsonMKLiYMurphyBRandomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology GroupJ Clin Oncol200523153562356715908667
   PubMed Web of Science ®Google Scholar
• ColevasADChemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neckJ Clin Oncol200624172644265216763278
   PubMed Web of Science ®Google Scholar
• DassonvilleOFormentoJLFrancoualMExpression of epidermal growth factor receptor and survival in upper aerodigestive tract cancerJ Clin Oncol19931110187318788410112
   PubMed Web of Science ®Google Scholar
• Rubin GrandisJMelhemMFBarnesELTweardyDJQuantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neckCancer1996786128412928826952
   PubMed Web of Science ®Google Scholar
• SantiniJFormentoJLFrancoualMCharacterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomasHead Neck19911321321392022478
   PubMed Web of Science ®Google Scholar
• Rubin GrandisJMelhemMFGoodingWELevels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survivalJ Natl Cancer Inst199890118248329625170
   PubMed Web of Science ®Google Scholar
• AngKKBerkeyBATuXImpact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinomaCancer Res200262247350735612499279
   PubMed Web of Science ®Google Scholar
• XiaWLauYKZhangHZCombination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family membersClin Cancer Res19995124164417410632356
   PubMed Web of Science ®Google Scholar
• O-charoenratPRhys-EvansPHArcherDJEcclesSAC-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factorsOral Oncol2002381738011755824
   PubMed Web of Science ®Google Scholar
• BazleyLAGullickWJThe epidermal growth factor receptor familyEndocr Relat Cancer200512Suppl 1S17S2716113093
   PubMed Web of Science ®Google Scholar
• HynesNELaneHAERBB receptors and cancer: the complexity of targeted inhibitorsNat Rev Cancer20055534135415864276
   PubMed Web of Science ®Google Scholar
• EgloffAMGrandisJRTargeting epidermal growth factor receptor and SRC pathways in head and neck cancerSemin Oncol200835328629718544443
   PubMed Web of Science ®Google Scholar
• BaselgaJArteagaCLCritical update and emerging trends in epidermal growth factor receptor targeting in cancerJ Clin Oncol200523112445245915753456
   PubMed Web of Science ®Google Scholar
• GanlyITalbotSCarlsonDIdentification of angiogenesis/metastases genes predicting chemoradiotherapy response in patients with laryngopharyngeal carcinomaJ Clin Oncol200725111369137617416856
   PubMed Web of Science ®Google Scholar
• TakikitaMXieRChungJYMembranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinomaJ Transl Med2011912621801427
   PubMed Web of Science ®Google Scholar
• BarkerFGSimmonsMLChangSMEGFR overexpression and radiation response in glioblastoma multiformeInt J Radiat Oncol Biol Phys200151241041811567815
   PubMed Web of Science ®Google Scholar
• ErjalaKSundvallMJunttilaTTSignaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cellsClin Cancer Res200612134103411116818711
   PubMed Web of Science ®Google Scholar
• Schmidt-UllrichRKMikkelsenRBDentPRadiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylationOncogene19971510119111979294612
   PubMed Web of Science ®Google Scholar
• BowersGReardonDHewittTThe relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cellsOncogene200120111388139711313882
   PubMed Web of Science ®Google Scholar
• ContessaJNHamptonJLammeringGIonizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cellsOncogene200221254032404112037685
   PubMed Web of Science ®Google Scholar
• DittmannKMayerCFehrenbacherBRadiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinaseJ Biol Chem200528035311823118916000298
   PubMed Web of Science ®Google Scholar
• DittmannKMayerCKehlbachRRodemannHPRadiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PKMol Cancer200876918789131
   PubMed Web of Science ®Google Scholar
• KavanaghBDLinPSChenPSchmidt-UllrichRKRadiation-induced enhanced proliferation of human squamous cancer cells in vitro: a release from inhibition by epidermal growth factorClin Cancer Res1995112155715629815956
   PubMed Web of Science ®Google Scholar
• AbholdELKiangARahimyEEGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cellsPLoS One201272e3245922384257
   PubMed Web of Science ®Google Scholar
• BozecAPeyradeFFischelJLMilanoGEmerging molecular targeted therapies in the treatment of head and neck cancerExpert Opin Emerg Drugs200914229931019519286
   PubMed Web of Science ®Google Scholar
• ERBITUX® (cetuximab) injection, for intravenous infusion [package insert]Branchburg, NJImClone LLC2013
   Google Scholar
• BonnerJAHarariPMGiraltJRadiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckN Engl J Med2006354656757816467544
   PubMed Web of Science ®Google Scholar
• BonnerJAHarariPMGiraltJRadiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalLancet Oncol2010111212819897418
   PubMed Web of Science ®Google Scholar
• PignonJPle MaîtreAMaillardEBourhisJMeta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patientsRadiother Oncol200992141419446902
   PubMed Web of Science ®Google Scholar
• AngKKZhangQRosenthalDIRandomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522J Clin Oncol201432272940295025154822
   PubMed Web of Science ®Google Scholar
• LefebvreJLPointreauYRollandFInduction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II studyJ Clin Oncol201331785385923341517
   PubMed Web of Science ®Google Scholar
• BurtnessBGoldwasserMAFloodWMattarBForastiereAAPhase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group studyJ Clin Oncol200523348646865416314626
   PubMed Web of Science ®Google Scholar
• VermorkenJBMesiaRRiveraFPlatinum-based chemotherapy plus cetuximab in head and neck cancerN Engl J Med2008359111116112718784101
   PubMed Web of Science ®Google Scholar
• YangXDJiaXCCorvalanJRWangPDavisCGDevelopment of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapyCrit Rev Oncol Hematol2001381172311255078
   PubMed Web of Science ®Google Scholar
• VermorkenJBStohlmacher-WilliamsJDavidenkoICisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trialLancet Oncol201314869771023746666
   PubMed Web of Science ®Google Scholar
• ChungCIsaranuwatchaiWDi MaioMEconomic analysis of TORCH: erlotinib versus cisplatin and gemcitabine as first-line therapy for advanced non-small cell lung cancer (NSCLC)J Clin Oncol201331Suppl Abstract e19031
   Google Scholar
• WirthLJDakhilSRKornekGPARTNER: a randomized phase II study of docetaxel/cisplatin (doc/cis) chemotherapy with or without panitumumab (pmab) as first-line treatment (tx) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)J Clin Oncol201331Suppl Abstract 6029
   Google Scholar
• GiraltJTrigoJMNuytsSPhase 2, randomized trial (CONCERT-2) of panitumumab (PMAB) plus radiotherapy (PRT) compared with chemoradiotherapy (CRT) in patients (PTS) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN) [Abstract 1016O]Ann Oncol201223Suppl 9ix334
   Google Scholar
• SiuLLWaldronJNChenBEPhase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trialJ Clin Oncol201533Suppl Abstract 6000
   Google Scholar
• RingashJWaldronJNSiuLLQuality of life (QOL) in a phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 (NCT00820248)J Clin Oncol201533Suppl Abstract 6053
   Google Scholar
• SchickUGujralDMRichardsTMHarringtonKJNuttingCMZalutumumab in head and neck cancerExpert Opin Biol Ther201212111912522171666
   PubMed Web of Science ®Google Scholar
• MachielsJPSubramanianSRuzsaAZalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trialLancet Oncol201112433334321377930
   PubMed Web of Science ®Google Scholar
• EriksenJGMaareCJohansenJDAHANCA 19: first results of a randomized phase III study of the importance of the EGFR-inhibitor zalutumumab for the outcome of primary curative radiotherapy for squamous cell carcinoma of the head and neckLate breaking abstract presented at: The European Cancer CongressSeptember 27–October 1, 2013Amsterdam, Netherlands Abstract 12
   Google Scholar
• BolandWKBebbGNimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicityExpert Opin Biol Ther2009991199120619624281
   PubMed Web of Science ®Google Scholar
• TalaveraAFriemannRGomez-PuertaSNimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformationCancer Res200969145851585919584289
   PubMed Web of Science ®Google Scholar
• RodriguezMORiveroTCdel CastilloBRNimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neckCancer Biol Ther20109534334920448462
   PubMed Web of Science ®Google Scholar
• BasavarajCSierraPShivuJMelarkodeRMonteroENairPNimotuzumab with chemoradiation confers a survival advantage in treatment-naive head and neck tumors over expressing EGFRCancer Biol Ther201010767368120647773
   PubMed Web of Science ®Google Scholar
• BhatnagarARSinghDPSharmaRA comparative study of monoclonal antibody against EGFR (nimotuzumab) used in combination with chemoradiation versus chemoradiation alone in the treatment of locally advanced inoperable squamous cell carcinoma of the head and neckJ Clin Oncol201230Suppl Abstract e16012
   Google Scholar
• KamathAVLuDGuptaPPreclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical doseCancer Chemother Pharmacol20126941063106922203367
   PubMed Web of Science ®Google Scholar
• SchaeferGHaberLCrockerLMA two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with mono-specific antibodiesCancer Cell201120447248622014573
   PubMed Web of Science ®Google Scholar
• HuangSLiCArmstrongEADual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiationCancer Res201373282483323172311
   PubMed Web of Science ®Google Scholar
• PedersenMWJacobsenHJKoefoedKSym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacyCancer Res201070258859720068188
   PubMed Web of Science ®Google Scholar
• MachielsJ-PHSpecenierPMKraussJSym004, a novel strategy to target EGFR with an antibody mixture, in patients with advanced SCCHN progressing after anti-EGFR monoclonal antibody: a proof of concept studyJ Clin Oncol201331Suppl Abstract 6002
   Google Scholar
• AdamoVFranchinaTAdamoBGefitinib in lung cancer therapy: Clinical results, predictive markers of response and future perspectivesCancer Biol Ther20098320621219182534
   PubMed Web of Science ®Google Scholar
• StewartJSCohenEELicitraLPhase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neckJ Clin Oncol200927111864187119289630
   PubMed Web of Science ®Google Scholar
• ArgirisAGhebremichaelMGilbertJPhase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an Eastern Cooperative Oncology Group trialJ Clin Oncol201331111405141423460714
   PubMed Web of Science ®Google Scholar
• CohenMHJohnsonJRChenYFSridharaRPazdurRFDA drug approval summary: erlotinib (Tarceva) tabletsOncologist200510746146616079312
   PubMed Web of Science ®Google Scholar
• Tarceva^® (erlotinib tablets) [package insert]South San Francisco, CAGenentech, Inc2013
   Google Scholar
• ThomasFRochaixPBenlyazidAPilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinomaClin Cancer Res200713237086709218056187
   PubMed Web of Science ®Google Scholar
• HerchenhornDDiasFLViegasCMPhase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neckInt J Radiat Oncol Biol Phys201078369670220421154
   PubMed Web of Science ®Google Scholar
• HainsworthJDSpigelDRGrecoFACombined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortiumCancer J201117526727221952273
   PubMed Web of Science ®Google Scholar
• MartinsRGParvathaneniUBaumanJECisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trialJ Clin Oncol201331111415142123460709
   PubMed Web of Science ®Google Scholar
• SoulieresDSenzerNNVokesEEHidalgoMAgarwalaSSSiuLLMulticenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neckJ Clin Oncol2004221778514701768
   PubMed Web of Science ®Google Scholar
• SiuLLSoulieresDChenEXPhase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group StudyJ Clin Oncol200725162178218317538162
   PubMed Web of Science ®Google Scholar
• KimESKiesMSGlissonBSFinal results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancerJ Clin Oncol20072518S Abstract 6013
   Google Scholar
• KondoNTsukudaMIshiguroYAntitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinomaOncol Rep201023495796320204279
   PubMed Web of Science ®Google Scholar
• TYKERB^® (lapatinib) tablets [package insert]Research Triangle Park, NCGlaxoSmithKline2012
   Google Scholar
• Del CampoJMHittRSebastianPEffects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neckBr J Cancer2011105561862721829197
   PubMed Web of Science ®Google Scholar
• de SouzaJADavisDWZhangYA phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neckClin Cancer Res20121882336234322371453
   PubMed Web of Science ®Google Scholar
• LalamiYSpecenierPMAwadaAEORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinomaRadiother Oncol2012105223824022989664
   PubMed Web of Science ®Google Scholar
• HarringtonKJTemamSD’CruzAFinal analysis: a randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN)J Clin Oncol2014325s Abstract 6005
   Google Scholar
• LiDAmbrogioLShimamuraTBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene200827344702471118408761
   PubMed Web of Science ®Google Scholar
• SolcaFDahlGZoephelATarget binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blockerJ Pharmacol Exp Ther2012343234235022888144
   PubMed Web of Science ®Google Scholar
• MachielsJPHaddadRIFayetteJAfatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialLancet Oncol201516558359425892145
   PubMed Web of Science ®Google Scholar
• CohenEEWFayetteLJGaulerTCBiomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1)J Clin Oncol201533Suppl Abstract 6023
   Google Scholar
• SeiwertTYFayetteJCupissolDA randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neckAnn Oncol20142591813182024928832
   PubMed Web of Science ®Google Scholar
• GonzalesAJHookKEAlthausIWAntitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitorMol Cancer Ther2008771880188918606718
   PubMed Web of Science ®Google Scholar
• Abdul RazakARSoulieresDLaurieSAA phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neckAnn Oncol201324376176923108949
   PubMed Web of Science ®Google Scholar
• WedgeSROgilvieDJDukesMZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administrationCancer Res200262164645465512183421
   PubMed Web of Science ®Google Scholar
• CAPRELSA^® (vandetanib) tablets [prescribing information]Wilmington, DEAstraZeneca Pharmaceuticals LP2011
   Google Scholar
• LimayeSRileySZhaoSA randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)Oral Oncol201349883584123727257
   PubMed Web of Science ®Google Scholar
• HansenARSiuLLEpidermal growth factor receptor targeting in head and neck cancer: have we been just skimming the surface?J Clin Oncol201331111381138323460713
   PubMed Web of Science ®Google Scholar
• KimuraHSakaiKAraoTShimoyamaTTamuraTNishioKAntibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptorCancer Sci20079881275128017498200
   PubMed Web of Science ®Google Scholar
• KalyankrishnaSGrandisJREpidermal growth factor receptor biology in head and neck cancerJ Clin Oncol200624172666267216763281
   PubMed Web of Science ®Google Scholar
• DebTBSuLWongLEpidermal growth factor (EGF) receptor kinase-independent signaling by EGFJ Biol Chem200127618155541556011279155
   PubMed Web of Science ®Google Scholar
• GusenbauerSVlaicuPUllrichAHGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitorsOncogene201332333846385623045285
   PubMed Web of Science ®Google Scholar
• WeihuaZTsanRHuangWCSurvival of cancer cells is maintained by EGFR independent of its kinase activityCancer Cell200813538539318455122
   PubMed Web of Science ®Google Scholar
• TanXThapaNSunYAndersonRAA kinase-independent role for EGF receptor in autophagy initiationCell20151601–214516025594178
   PubMed Web of Science ®Google Scholar
• DienstmannRBranaIRodonJTaberneroJToxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugsOncologist201116121729174022135123
   PubMed Web of Science ®Google Scholar
• CohenEEKaneMAListMAPhase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckClin Cancer Res200511238418842416322304
   PubMed Web of Science ®Google Scholar
• SolomonBMJatoiARash from EGFR inhibitors: opportunities and challenges for palliationCurr Oncol Rep200810430430818778556
   PubMed Web of Science ®Google Scholar
• LauxIJainASinghSAgusDBEpidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapiesBr J Cancer2006941859216306877
   PubMed Web of Science ®Google Scholar
• SalamaJKHaddadRIKiesMSClinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancerInt J Radiat Oncol Biol Phys200975372573319362781
   PubMed Web of Science ®Google Scholar
• MesiaRRuedaAVeraRAdjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trialAnn Oncol201324244845323041591
   PubMed Web of Science ®Google Scholar
• MarurSLeeJ-WCmelakAECOG 1308: a phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP)J Clin Oncol201230Suppl Abstract 5566
   Google Scholar
• MarurSLiSCmelakAE 1308: a phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC)J Clin Oncol201331Suppl Abstract 6005
   Google Scholar
• MassarelliEHaddadRILeeJJWeekly paclitaxel, carboplatin, cetuximab (PCC), and cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF), followed by risk-based local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (LAHN-SCC)J Clin Oncol201533Suppl Abstract 6001
   Google Scholar
• GuigayJFayetteJDilliesAFCetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): final results of phase II trial GORTEC 2008-03J Clin Oncol201230Suppl Abstract 5505
   Google Scholar
• HittRIrigoyenACortes-FunesHGrauJJGarcia-SaenzJACruz-HernandezJJPhase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neckAnn Oncol20122341016102221865152
   PubMed Web of Science ®Google Scholar
• BaselgaJTrigoJMBourhisJPhase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neckJ Clin Oncol200523245568557716009950
   PubMed Web of Science ®Google Scholar
• KnoedlerMDietzAGaulerTCCetuximab, fluorouracil (5-FU), cisplatin, and docetaxel as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): interim results of a randomized phase II clinical trial (CeFCiD)J Clin Oncol201331Suppl Abstract e17021
   Google Scholar
• VermorkenJBLicitraLStohlmacher-WilliamsJPhase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neckEur J Cancer201349132877288323726971
   PubMed Web of Science ®Google Scholar
• HerbstRSArquetteMShinDMPhase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neckJ Clin Oncol200523245578558716009949
   PubMed Web of Science ®Google Scholar
• FuryMGShermanELisaDA randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancerJ Natl Compr Canc Netw201210111391139823138167
   PubMed Web of Science ®Google Scholar
• VermorkenJBTrigoJHittROpen-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapyJ Clin Oncol200725162171217717538161
   PubMed Web of Science ®Google Scholar
• CrombetTOsorioMCruzTUse of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patientsJ Clin Oncol20042291646165415117987
   PubMed Web of Science ®Google Scholar
• HarringtonKBerrierARobinsonMRandomised phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative diseaseEur J Cancer20134971609161823265705
   PubMed Web of Science ®Google Scholar
• WaldronJNParulekarWO’SullivanBA phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6)J Clin Oncol201230Suppl Abstract TPS5600
   Google Scholar